Drugs / Replens
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT03185169 | Nov 2016 → Jul 2018 | female breast carcinoma, urinary tract infection, urogenital tract malformation, vaginal disorder | Alta Bates Summit Medical Center | Terminated | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01984138 Comparator | Sep 2013 → Jun 2025 overdue | estrogen-receptor positive breast cancer | Polly A. Niravath, MD | Active not recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06176820 Comparator | Jan → Jul 2024 | postmenopausal atrophic vaginitis, sexual disorder | Sarawak General Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Replens | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03185169 ↗ |
| Known as | Vaginal lubricant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06176820 ↗ |
| Route | Other | “intravaginally” NCT06176820 ↗ |